AI Engines For more Details: Perplexity Kagi Labs You
Schistosomiasis (Bilharzia): Niridazole is most commonly used to treat schistosomiasis, a parasitic disease caused by Schistosoma parasites. These parasites enter the body through the skin when individuals come into contact with contaminated water in regions where the disease is endemic. Once inside the body, the parasites migrate to blood vessels surrounding the intestines or bladder, where they lay eggs, leading to symptoms such as abdominal pain, diarrhea, blood in the urine, and liver and spleen enlargement. Niridazole works by killing the adult worms and reducing the severity of symptoms associated with schistosomiasis.
Liver Fluke Infections: In addition to its efficacy against Schistosoma parasites, niridazole may also be used to treat infections caused by liver flukes (e.g., Fasciola hepatica). These parasitic worms can infect the liver and bile ducts, leading to symptoms such as abdominal pain, jaundice, and liver dysfunction. Niridazole helps eliminate the parasites from the body and alleviate associated symptoms.
Side Effects: While niridazole is effective against parasitic infections, it can cause various side effects, including gastrointestinal disturbances (e.g., nausea, vomiting, abdominal discomfort), headache, dizziness, skin rash, and neurological symptoms (e.g., drowsiness, confusion). Rarely, severe adverse reactions such as hepatotoxicity (liver damage) and neurological toxicity may occur, necessitating careful monitoring during treatment.
Cautions and Contraindications: Niridazole should be used with caution in individuals with liver or kidney impairment, as well as those with a history of neurological disorders. It is contraindicated in pregnant women and individuals with a known hypersensitivity to the drug. Due to the risk of adverse effects, the use of niridazole should be carefully weighed against the potential benefits, and patients should be monitored closely during treatment.
Treatment Regimen: The treatment regimen for schistosomiasis and other parasitic infections with niridazole typically involves a specific dosage and duration of therapy prescribed by a healthcare professional based on the severity of the infection and individual patient factors. Compliance with the prescribed regimen is essential to ensure effective treatment and minimize the risk of drug resistance.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.5 | -0.5 | |
| ADHD | 7.5 | 1 | 6.5 |
| Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
| Allergic Rhinitis (Hay Fever) | 3 | 2.5 | 0.2 |
| Allergies | 7.5 | 4.5 | 0.67 |
| Allergy to milk products | 2.5 | 1.5 | 0.67 |
| Alopecia (Hair Loss) | 2.5 | 2.5 | |
| Alzheimer's disease | 6.5 | 10 | -0.54 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 6 | 2.5 | 1.4 |
| Ankylosing spondylitis | 6.5 | 3 | 1.17 |
| Anorexia Nervosa | 0.5 | 3.5 | -6 |
| Antiphospholipid syndrome (APS) | 3.5 | 0.5 | 6 |
| Asthma | 2 | 2.5 | -0.25 |
| Atherosclerosis | 2 | 3.5 | -0.75 |
| Atrial fibrillation | 5.5 | 3.5 | 0.57 |
| Autism | 16.5 | 15.5 | 0.06 |
| Barrett esophagus cancer | 1 | 0.5 | 1 |
| benign prostatic hyperplasia | 0.5 | 0.5 | |
| Bipolar Disorder | 2.5 | 2.5 | 0 |
| Brain Trauma | 1 | 1 | 0 |
| Carcinoma | 6 | 4 | 0.5 |
| Celiac Disease | 4 | 6.5 | -0.63 |
| Cerebral Palsy | 2.5 | 2 | 0.25 |
| Chronic Fatigue Syndrome | 8.9 | 10 | -0.12 |
| Chronic Kidney Disease | 4 | 3 | 0.33 |
| Chronic Lyme | 1 | -1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 3.5 | 1.5 | 1.33 |
| Chronic Urticaria (Hives) | 3 | 3 | 0 |
| Coagulation / Micro clot triggering bacteria | 2.5 | 2 | 0.25 |
| Colorectal Cancer | 8 | 1.5 | 4.33 |
| Constipation | 2.5 | 1 | 1.5 |
| Coronary artery disease | 2.5 | 1.5 | 0.67 |
| COVID-19 | 19 | 23 | -0.21 |
| Crohn's Disease | 13.5 | 9.5 | 0.42 |
| cystic fibrosis | 1.5 | 1.5 | 0 |
| deep vein thrombosis | 1.5 | 1.5 | 0 |
| Depression | 16.4 | 13.9 | 0.18 |
| Dermatomyositis | 0.5 | 0.5 | 0 |
| Eczema | 2 | 3.5 | -0.75 |
| Endometriosis | 5 | 2 | 1.5 |
| Eosinophilic Esophagitis | 0.5 | 0.5 | 0 |
| Epilepsy | 5 | 4.5 | 0.11 |
| Fibromyalgia | 4.5 | 4.5 | 0 |
| Functional constipation / chronic idiopathic constipation | 9.5 | 6.5 | 0.46 |
| gallstone disease (gsd) | 3.5 | 1.5 | 1.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 3 | 1.5 | 1 |
| Generalized anxiety disorder | 3.5 | 3 | 0.17 |
| giant cell arteritis | 0.5 | -0.5 | |
| Glioblastoma | 0.5 | -0.5 | |
| Gout | 0.5 | -0.5 | |
| Graves' disease | 2 | 2 | 0 |
| Halitosis | 1.5 | 0.5 | 2 |
| Hashimoto's thyroiditis | 4 | 1.5 | 1.67 |
| Hidradenitis Suppurativa | 1.5 | 0.5 | 2 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 5.5 | 1.5 | 2.67 |
| hypercholesterolemia (High Cholesterol) | 1 | 1 | 0 |
| hyperglycemia | 0.5 | 3.5 | -6 |
| Hyperlipidemia (High Blood Fats) | 1.5 | 0.5 | 2 |
| hypersomnia | 1 | -1 | |
| hypertension (High Blood Pressure | 4 | 8 | -1 |
| Hypothyroidism | 2 | -2 | |
| Hypoxia | 1.5 | 1.5 | |
| IgA nephropathy (IgAN) | 7 | -7 | |
| Inflammatory Bowel Disease | 8 | 14 | -0.75 |
| Insomnia | 1.5 | 1.5 | 0 |
| Intelligence | 2 | 1 | 1 |
| Intracranial aneurysms | 2 | 0.5 | 3 |
| Irritable Bowel Syndrome | 7.5 | 7 | 0.07 |
| Liver Cirrhosis | 8 | 5.5 | 0.45 |
| Long COVID | 14 | 14 | 0 |
| Low bone mineral density | 1.5 | -1.5 | |
| Lung Cancer | 1.5 | 2.5 | -0.67 |
| ME/CFS with IBS | 2 | 4 | -1 |
| ME/CFS without IBS | 3.5 | 3.5 | 0 |
| Menopause | 3 | 3 | |
| Metabolic Syndrome | 13.5 | 14.3 | -0.06 |
| Mood Disorders | 21.4 | 14.4 | 0.49 |
| multiple chemical sensitivity [MCS] | 2.5 | 0.5 | 4 |
| Multiple Sclerosis | 10 | 9 | 0.11 |
| Multiple system atrophy (MSA) | 3.5 | 1.5 | 1.33 |
| Neuropathy (all types) | 1.5 | 0.5 | 2 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.5 | 1.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4 | 8.5 | -1.13 |
| NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
| Obesity | 14 | 8.4 | 0.67 |
| obsessive-compulsive disorder | 11 | 7.5 | 0.47 |
| Osteoarthritis | 4 | 0.5 | 7 |
| Osteoporosis | 3 | 2 | 0.5 |
| pancreatic cancer | 1 | 1 | |
| Parkinson's Disease | 6 | 7 | -0.17 |
| Polycystic ovary syndrome | 4 | 3.5 | 0.14 |
| Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
| Premenstrual dysphoric disorder | 1.5 | 0.5 | 2 |
| primary biliary cholangitis | 0.5 | 1.5 | -2 |
| Psoriasis | 7.5 | 5 | 0.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 11.5 | 6 | 0.92 |
| Rosacea | 2 | 1 | 1 |
| Schizophrenia | 11.5 | 3 | 2.83 |
| scoliosis | 0.5 | 2 | -3 |
| Sjögren syndrome | 5 | 5 | 0 |
| Sleep Apnea | 2.5 | 2.5 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 1 | 1 |
| Stress / posttraumatic stress disorder | 5 | 4.5 | 0.11 |
| Systemic Lupus Erythematosus | 7.5 | 3 | 1.5 |
| Tic Disorder | 2 | 2.5 | -0.25 |
| Tourette syndrome | 0.5 | 0.5 | 0 |
| Type 1 Diabetes | 6.5 | 4 | 0.63 |
| Type 2 Diabetes | 14 | 12.3 | 0.14 |
| Ulcerative colitis | 4.9 | 9.5 | -0.94 |
| Unhealthy Ageing | 10.5 | 3.5 | 2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.